Holen Sie sich die Stockscreener-App
37.38
2.61%
0.95
Handel nachbörslich:
37.38
Schlusskurs vom Vortag:
$36.43
Offen:
$36.84
24-Stunden-Volumen:
1.25M
Relative Volume:
1.19
Marktkapitalisierung:
$3.28B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-17.07
EPS:
-2.19
Netto-Cashflow:
$-134.36M
1W Leistung:
+10.43%
1M Leistung:
+9.68%
6M Leistung:
+62.73%
1J Leistung:
+50.42%
1-Tages-Spanne:
$36.63
$38.03
1-Wochen-Bereich:
$32.59
$39.28
52-Wochen-Spanne:
$13.45
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
37.38 | 3.19B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-09-04 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Why IDEAYA Biosciences Inc. stock attracts global investors2025 Market Overview & Safe Capital Growth Stock Tips - ulpravda.ru
How buybacks impact IDEAYA Biosciences Inc. stock valueTrail vs Road Selection & HOKA model picks for your routine - ulpravda.ru
Why IDEAYA Biosciences Inc. stock is considered a top pickFit and Size Notes & walk-ready comfort choices - ulpravda.ru
GSK ends collaboration with IDEAYA for two candidates - MSN
How analysts rate IDEAYA Biosciences Inc. stock todayTake Profit & Safe Capital Growth Tips - ulpravda.ru
Why IDEAYA Biosciences Inc. stock remains on buy listsJuly 2025 Short Interest & Smart Money Movement Tracker - ulpravda.ru
What downside risks could hit IDEAYA Biosciences Inc. (30J) stockQuarterly Portfolio Review & Verified Entry Point Detection - ulpravda.ru
Ideaya Biosciences stock hits 52-week high at 37.09 USD By Investing.com - Investing.com Nigeria
Ideaya Biosciences stock hits 52-week high at 37.09 USD - Investing.com
Ideaya Biosciences stock gets Buy rating from UBS with $50 price target - Investing.com Canada
Will IDEAYA Biosciences Inc. stock rally after Fed decisions2026 world cup usa national team group stage star players high defensive line odds analysis guide - ulpravda.ru
Will IDEAYA Biosciences Inc. stock outperform growth indexes2026 world cup usa national team third place match goalkeepers possession football group prediction preview - ulpravda.ru
Truist Securities raises Ideaya Biosciences stock price target to $60 By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference | IDYA Stock News - Longbridge
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - Quantisnow
Buyback Watch: Can IDEAYA Biosciences Inc 30J stock ride next bull market cycleJuly 2025 Movers & AI Powered Trade Plan Recommendations - moha.gov.vn
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Nasdaq 100 Index Research-Driven Model - Kalkine Media
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Sees Unusually Large Options Volume (NASDAQ:IDYA) - MarketBeat
Will IDEAYA Biosciences Inc. stock benefit from commodity pricesCandlestick Trading Patterns & Next-Level Stock Intelligence, Now Free - bollywoodhelpline.com
IDEAYA Biosciences Earnings Notes - Trefis
Squarepoint Ops LLC Sells 51,937 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers - Nasdaq
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
How IDEAYA Biosciences Inc. (30J) stock compares with tech leaders2025 Technical Patterns & Community Supported Trade Ideas - Улправда
Why IDEAYA Biosciences Inc. stock attracts high net worth investorsJuly 2025 Price Swings & Weekly High Return Stock Opportunities - Улправда
Aug EndMonth: Why IDEAYA Biosciences Inc. stock attracts high net worth investorsStock Surge & Accurate Trade Setup Notifications - Улправда
Why IDEAYA Biosciences Inc. stock appeals to dividend seekersQuarterly Profit Summary & Precise Swing Trade Alerts - Улправда
How interest rate cuts could boost IDEAYA Biosciences Inc. stockChart Signals & Consistent Return Investment Signals - Улправда
Gap Down: Will IDEAYA Biosciences Inc. stock outperform growth indexesJuly 2025 Update & Expert-Curated Trade Recommendations - Улправда
Why IDEAYA Biosciences Inc. (30J) stock remains top ratedPortfolio Return Summary & AI Powered Buy and Sell Recommendations - DonanımHaber
How supply shortages influence IDEAYA Biosciences Inc. (30J) stockJuly 2025 Pullbacks & Low Risk Investment Opportunities - Улправда
Aug Weekly: Why IDEAYA Biosciences Inc. stock attracts high net worth investorsTrade Signal Summary & Weekly Momentum Picks - Улправда
Antibody Optimization Service Market Set to Reach USD 6.07 Billion by 2034, Growing at an 8.45% CAGR Amid Advances in Gene-Editing Technologies - GlobeNewswire Inc.
IDEAYA Biosciences (IDYA): Valuation Check After Key Darovasertib Trial Milestone and Pipeline Progress - simplywall.st
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial - Yahoo Finance
Ideaya Biosciences to regain rights for two programs as GSK ends partnership - Investing.com Australia
Ideaya Biosciences to regain rights for two programs as GSK ends partnership By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ: IDYA) outlines GSK exit, program transfer and cash runway - Stock Titan
Redmile Group LLC Sells 102,106 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA financials not impacted by GSK termination, says Mizuho - MSN
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma - RTTNews
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
IDEAYA completes enrollment for pivotal cancer drug trial - Investing.com
IDEAYA completes enrollment for pivotal cancer drug trial By Investing.com - Investing.com South Africa
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - BioSpace
Stempoint Capital LP Purchases 98,886 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):